Fire Needling Plus Filiform Needling for Chronic Migraine With Comorbid Tension-Type Headache

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorBeijing Hospital of Traditional Chinese Medicine

About this trial

The investigators conducted a multicenter, prospective, randomized controlled clinical study to learn whether fire needling combined with filiform needling applied to pericranial muscle tenderness areas can effectively treat chronic migraine with comorbid tension-type headache. The study will also evaluate the safety and long-term efficacy of this therapy. Its main target questions include:

1. Can fire needling significantly reduce the number of headache days per month? 2. What is the effect of this therapy on headache intensity, emotional symptoms, and quality of life? The investigators will compare "fire needling at pericranial tender points plus conventional filiform needling" versus "conventional filiform needling alone" to verify whether the key technique of fire needling plus conventional filiform needling provides unique additive value.

Participants will:

1. Receive treatment twice per week for 8 weeks (either in the experimental group or the control group),attend a follow-up visit at week 24 after enrollment 2. Keep a headache diary (recording headache frequency, pain intensity, duration, associated symptoms, etc.) 3. Regularly complete assessments of emotional status, quality of life, and number of pericranial tender points

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Meets the diagnostic criteria for tension-type headaches with pericranial tenderness;

Meets the diagnostic criteria for chronic migraine;

18 years ≤ age ≤ 65 years;

Has sufficient understanding to complete the necessary examinations and tests for the study;

Disqualifiers

Patients complicated with cluster headache or other primary headaches;

Patients with secondary headaches caused by intracranial space-occupying lesions, cranial infections, etc.;

Patients complicated with severe heart, liver or kidney impairment, coagulation disorders, infections, severe immunocompromise, or allergic predisposition;

Patients with alcohol or drug dependence;

Trial design

Design model

Parallel

Treatments tested in this trial

  • filiform needling

    Procedure/Surgery

    Selection of acupoints for filiform needle therapy is integrated with the international standard acupuncture preventive treatment protocol for migraine specified in Acupuncture Clinical Practice Guidelines for Migraine issued by the World Federation of Acupuncture-Moxibustion Societies (WFAS 007.8-2023).Treatment was administered twice weekly for 8 weeks. Main Acupoints: Baihui (GV20), Shenting (GV24), Fengchi (GB20, bilateral), Benshen (GB13, bilateral), Shuaigu (GB8, bilateral), Taiyang (EX-HN5, bilateral). Adjunct Acupoints: For shaoyang headache: add Toulinqi (GB15), Yangbai (GB14), Fubai (GB10), Zulinqi (GB41), Waiguan (SJ5), Yanglingquan (GB34); For yangming headache: add Touwei (ST8), Hegu (LI4), Neiting (ST44); For taiyang headache: add Kunlun (BL60), Houxi (SI3); For jueyin headache: add Taichong (LR3), Qiuxu (GB40).

  • fire needling combined with filiform needling

    Procedure/Surgery

    Fire needling was used to puncture pericranial muscle tenderness areas (including the external occipital protuberance, superior nuchal line, nuchal plane, mastoid process; cervicoscapular areas; epicranial aponeurosis - frontal and temporal regions; upper trapezius, sternocleidomastoid, levator scapulae, temporalis, masseter, and occipitofrontalis muscles) in addition to filiform needling at meridian acupoints (same acupoints as the filiform needling group). Treatment was administered twice weekly for 8 weeks.

Treatment groups

88 Participants
are divided into 2 treatment groups
Group A: filiform needlingActive comparator 1 intervention
Group B: fire needling combined with filiform needlingExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Treatment efficacy

Based on the statistics from the headache diaries completed by patients, it is defined as the proportion of subjects who achieve a reduction in headache days of ≥50% after treatment compared to before treatment.

Time frame
At week 8 of treatment, and follow-up at week 24 of enrollment

Secondary outcomes

1

Headache days

Time frame
Baseline, at week 8 of treatment, and follow-up at week 24 of enrollment.
2

Headache Duration

Time frame
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
3

Headache severity

Time frame
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.
4

The proportion of monthly headache attacks occurring ≤1 time per month

Time frame
Baseline, at week 8 of treatment, and 24 weeks after enrollment follow-up.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Beijing Hospital of Traditional Chinese Medicine

Lead sponsor

Capital's Funds for Health Improvement and Research

Collaborator

This trial is not recruiting at the moment. You can still explore other options: